Free Daily Podcast Summary
The BioCentury Show: Daily Summaries Delivered
by BioCentury
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 3 days ago34 min
Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile
On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets. Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition...
- 2 weeks ago31 min
Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets
On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics. View full story: https://www.biocentury.com/article/660697 #Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials 0:00 - Introduction 1:14 - Regeneron Genetics Center 10:29 - Acting on Genetic Signals 16:57 ...
- Aug 21, 202629 min
Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient
The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to bring form to FDA’s Plausible Mechanism Framework by standardizing how evidence and methods can be reused across therapies and patients. In conversation with Biopharma Analyst Dr. Tierney Baum on The BioCentury Show, C-Path CEO and CSO Klaus Romero ...
- Aug 7, 202632 min
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biot...
- Jul 23, 202640 min
Ep. 115 - Initiate's Owens on what it takes to be AI-native
As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show, Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model. Owens also discusses gaps in evidence generation for diagnostics, and closes ...
- Jul 10, 202641 min
Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model
Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year. In conversation with Lindsay Martin on The BioCentury Show, Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its ...
- Jun 25, 202635 min
Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking
Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank Jiang, EVP and chief strategy officer, Hengrui is engaging in a range of dealmaking and using its partnerships as stepping stones toward its goal of becoming one of the top biopharma companies in the world. In conversation with Executive Editor Jeff Cranmer on The BioCent...
- Jun 18, 202640 min
Ep. 112 - Chris Arendt on rebuilding Takeda for AI
Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development. View full story: https://www.biocentury.com/article/659807 #Artif...
About The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The BioCentury Show in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The BioCentury Show daily summary?
It's a free AI-powered email that summarizes new episodes of The BioCentury Show as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The BioCentury Show podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The BioCentury Show product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by BioCentury.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The BioCentury Show release new episodes?
The BioCentury Show publishes biweekly. Our AI generates a summary within hours of each new episode.
What topics does The BioCentury Show cover?
The BioCentury Show covers topics including Science, Business, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The BioCentury Show summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.